Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LINEZOLID

All injection strengths: not a benefit

Linezolid Injection · DIN 02481278 · 2mg/mL · injection-300mL Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Linezolid Injection · DIN 02481278 Manufacturer: Jamp Pharma Corporation; listing date 2020-05-29 Health Canada: Marketed since 2019-12-30 · brand LINEZOLID INJECTION · ATC J01XX08 LINEZOLID · form Solution · route Intravenous · ingredients LINEZOLID 2 MG/ML · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Linezolid Injection: Formulary list price $88.7400/unit (unit not stated in source; not the patient's cost)

Ministry pays: $88.7400 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97176 · Verify on the e-Formulary ↗ (DIN 02481278)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02481278). DIN 02481278: Linezolid Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 084000068; group id 135; item number 0228; lccId None; manufacturer id JPC Source form: Inj-300mL Pk; strength: 2mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $88.7400; ministry $88.7400 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02481278 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97176
Interchangeable products
Zyvoxam · DIN 02243685 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02481278
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (08:40 Miscellaneous Anti-Infectives) and how they are covered

Matched class: 08:40 Miscellaneous Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): CIPROFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN HYDROCHLORIDE, NORFLOXACIN, SULFAMETHOXAZOLE & TRIMETHOPRIM, TRIMETHOPRIM 08:40 Miscellaneous Anti-Infectives

CIPROFLOXACIN

· 44 products · Limited Use, codes 533 (1), Listed, not a benefit (3), General benefit (40) · strengths: 10g/100mL, 250mg, 500mg, 750mg · Oral Susp, Tab

LEVOFLOXACIN

· 24 products · Listed, not a benefit (2), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 250mg, 500mg, 750mg · Tab

MOXIFLOXACIN HYDROCHLORIDE

· 12 products · Listed, not a benefit (1), General benefit (11) · strengths: 400mg · Tab

NORFLOXACIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 400mg · Tab

SULFAMETHOXAZOLE & TRIMETHOPRIM

· 9 products · Listed, not a benefit (6), General benefit (3) · strengths: 40mg & 8mg/mL, 400mg & 80mg, 800mg & 160mg · O/L, Tab

TRIMETHOPRIM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mg, 200mg · Tab

CIPROFLOXACIN HCL & CIPROFLOXACIN BASE

· 2 products · Listed, not a benefit (1), Limited Use, codes 394 (1) · strengths: 500mg · ER Tab

CEFEPIME

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g, 2g · Inj Pd-Vial Pk

ERTAPENEM

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial · Inj Pd-Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:40
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS ZYVOXAM (linezolid injection and powder for oral suspension) is indicated for: Treatment of adult patients with the following infections, when caused by susceptible strains of the designated aerobic Gram-positive micro-organisms: Note: ZYVOXAM is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see 7 WARNINGS AND PRECAUTIONS). Vancomycin-Resistant Enterococcus faecium (VREF) Infections: ZYVOXAM is indicated for the treatment of the following infections when due to VREF: • Intra-abdominal, skin and skin-structure, and urinary tract infections (including cases associated with concurrent bacteremia) (see 14 CLINICAL TRIALS). Note: This indication for VREF is based on non-comparative studies. Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (penicillin-susceptible strains only). Community-acquired pneumonia caused by Streptococcus pneumoniae (penici… https://pdf.hres.ca/dpd_pm/00074542.PDF PM date: APR 02, 2001 Source product: ZYVOXAM; DIN 02243685; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Linezolid Injection: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026